Azerbaijan National Academy of Sciences

Novavax, Inc. announced the enrollment of the first participants in the second phase of the ongoing clinical trial evaluating the immunogenicity and safety of the vaccine candidate NVX-CoV2373 against COVID-19. The Phase 2 clinical trial expands the age range of Phase 1 participants to include older adults aged 60-84, who make up approximately 50% of the study participants.